SCHERING AG LICENSES SEGRA COMPOUND FOR OPHTHALMIC USE TO BAUSCH & LOMB

Schering AG, Germany and Bausch & Lomb announced that Schering has granted an exclusive worldwide license to Bausch & Lomb to develop and market a selective glucocorticoid receptor agonist (SEGRA) for the non-systemic treatment of eye disorders.

Yahoo Finance (http://biz.yahoo.com/prnews/060918/ukm016.html?.v=58)